Publicacións nas que colabora con Javier Costas Costas (41)

2023

  1. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  2. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2021

  1. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. Interaction between the functional SNP rs2070951 in NR3C2 gene and high levels of plasma corticotropin-releasing hormone associates to postpartum depression

    Archives of Women's Mental Health, Vol. 23, Núm. 3, pp. 413-420

  2. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529

  3. Psychiatric comorbidities in Asperger syndrome are related with polygenic overlap and differ from other Autism subtypes

    Translational Psychiatry, Vol. 10, Núm. 1

  4. The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme

    Social Psychiatry and Psychiatric Epidemiology, Vol. 55, Núm. 5, pp. 645-657

2019

  1. Assessing cross-national invariance of the Community Assessment of Psychic Experiences (CAPE)

    Psychological Medicine, Vol. 49, Núm. 15, pp. 2600-2607

  2. BDNF genetic variants and methylation: effects on cognition in major depressive disorder

    Translational Psychiatry, Vol. 9, Núm. 1

  3. Do polygenic risk and stressful life events predict pharmacological treatment response in obsessive compulsive disorder? A gene–environment interaction approach

    Translational Psychiatry, Vol. 9, Núm. 1

  4. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study

    The Lancet Psychiatry, Vol. 6, Núm. 5, pp. 427-436

2018

  1. FKBP5 polymorphisms and hypothalamic-pituitary-adrenal axis negative feedback in major depression and obsessive-compulsive disorder

    Journal of Psychiatric Research, Vol. 104, pp. 227-234

  2. Identification of genes carrying rare variants of moderate to large effect in schizophrenia: A replication study

    Schizophrenia Research

  3. Identification of putative second genetic hits in schizophrenia carriers of high-risk copy number variants and resequencing in additional samples

    European Archives of Psychiatry and Clinical Neuroscience, Vol. 268, Núm. 6, pp. 585-592

  4. Treated incidence of psychotic disorders in the multinational EU-GEI study

    JAMA Psychiatry, Vol. 75, Núm. 1, pp. 36-46

2016

  1. Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia

    Translational Psychiatry, Vol. 6, Núm. 3

  2. Targeted resequencing of regulatory regions at schizophrenia risk loci: Role of rare functional variants at chromatin repressive states

    Schizophrenia Research, Vol. 174, Núm. 1-3, pp. 10-16

2015

  1. An efficient screening method for simultaneous detection of recurrent copy number variants associated with psychiatric disorders

    Clinica Chimica Acta, Vol. 445, pp. 34-40

  2. Resequencing and association analysis of coding regions at twenty candidate genes suggest a role for rare risk variation at AKAP9 and protective variation at NRXN1 in schizophrenia susceptibility

    Journal of Psychiatric Research, Vol. 66-67, pp. 38-44

2014

  1. Common variant at 16p11.2 conferring risk of psychosis

    Molecular Psychiatry, Vol. 19, Núm. 1, pp. 108-114